Are you looking for expert advice...

Together with the Cannabis Industry Council and Drug Science, the Medical Cannabis Clinicians Society is pleased to announce the first-ever Cannabis Industry Awards. 

The event is being held during Medical Cannabis Awareness Week, making it a fitting occasion to celebrate excellence in the UK cannabis sector.

The Cannabis Industry Awards is set to be a key event for the UK cannabis community. It will bring together professionals from across the industry, including CEOs, founders, doctors, scientists, and other leading figures. Guests will enjoy a three-course meal, with entertainment provided by a comedian and table magicians. Following the dinner, there will be an after-party at a nearby venue, offering further opportunities to connect and celebrate.

About the Awards

The evening will feature two awards: the Social Impact Award and the Contribution to Science Award. These awards are designed to recognise individuals who have made notable contributions to the cannabis industry. 

Nominations are open from 2 September to 1 October, with a public vote from 4 to 25 October to decide the winners, reflecting the views and values of both industry insiders and the wider community.

Dr Leon Barron, Chair of the Medical Cannabis Clinicians Society, said:

“The Cannabis Industry Awards Dinner is a chance for us to come together and celebrate the progress we’ve made in the UK cannabis sector, particularly in improving access for patients and supporting clinicians in prescribing since 2018. These awards recognise the hard work and dedication of individuals who are helping to shape the future of the industry in two key areas. I’m looking forward to what will undoubtedly be a memorable evening.”

Buy your tickets 

To purchase your tickets, visit the official Eventbrite page. 

Book Your Tickets

 

Sponsorship Opportunities Available

While the Contribution to Science Award has been sponsored by Gowling WLG, there is still an opportunity for an organisation to sponsor the Social Impact Award. This sponsorship offers a chance to show support for social responsibility within the cannabis industry.

How Starling Bank Reshaped Digital Payments for UK Bettors, Explored by Betzella

When Starling Bank launched its current account in 2017, few in the gambling industry anticipated how significantly a mobile-first challenger bank would alter the relationship between UK bettors and their finances. Unlike traditional high street banks, which had spent decades building payment infrastructure around physical branches and legacy systems, Starling entered the market with an architecture designed entirely around real-time data, instant notifications, and granular user controls. For the millions of UK adults who bet regularly on sports, casino games, or other licensed gambling products, this represented a meaningful shift in how deposits and withdrawals could be managed with precision and transparency.

The Architecture Behind Starling’s Payment Controls

Starling Bank operates on a proprietary core banking platform rather than the outsourced or decades-old systems that underpin most established UK banks. This matters for bettors because it allows the bank to process transactions and deliver push notifications in genuine real-time — typically within seconds of a payment being initiated. When a customer deposits funds at a licensed betting operator, they receive an immediate notification detailing the merchant name, the amount, and a running balance. This level of transparency was largely absent from traditional banking before the challenger bank era.

More structurally significant is Starling’s Gambling Block feature, introduced in 2018. Unlike the blunt spending freezes offered by some competitors, Starling’s implementation allows customers to toggle gambling transactions off entirely through the app, with the change taking effect almost immediately. The block operates at the Merchant Category Code (MCC) level — specifically MCC 7995, which covers betting, casino gaming, and lottery transactions — meaning it applies across all licensed gambling merchants without requiring the customer to specify individual operators. This approach aligns with recommendations that emerged from the UK Gambling Commission’s ongoing work on safer gambling tools, which has consistently emphasised the importance of friction-reducing mechanisms for self-exclusion.

The bank also introduced spending insights that categorise gambling expenditure separately from other discretionary spending, giving customers a clear month-by-month view of what they are committing to betting activity. For bettors who track their own profitability or manage a defined recreational budget, this categorisation removes the manual work of reviewing statements and identifying individual transactions across multiple operators.

How Starling Fits into the Broader UK Betting Payment Landscape

The UK online gambling market processed an estimated £14.3 billion in gross gambling yield during the 2022–23 financial year, according to Gambling Commission data, with remote betting and casino products accounting for the substantial majority of that figure. The payment methods underpinning those transactions have evolved considerably since the early days of online betting, moving from predominantly debit card and bank transfer arrangements toward a more fragmented ecosystem that includes e-wallets, prepaid cards, and open banking solutions.

Starling sits within this landscape as a bank account rather than a payment intermediary, which carries specific implications. Deposits made from a Starling account to a licensed UK operator are treated as standard debit card transactions processed through the Mastercard network — Starling issues Mastercard debit cards to its customers. This means they benefit from the same consumer protections applicable to debit card payments while also gaining the bank-level controls described above. Withdrawals from betting accounts back to Starling typically complete within one to three business days, consistent with standard UK faster payments timelines, though some operators have integrated more rapid payout processes.

For bettors researching which banking options are compatible with specific operators, resources such as https://www.betzella.com/starling-bank-betting-sites/ provide structured information on which licensed platforms accept Starling deposits and withdrawals, a practical reference given that operator payment policies vary and are updated periodically. The compatibility question is not trivial: some operators have historically imposed restrictions on certain challenger bank cards, though this has become less common as digital banks have grown their customer bases and established clearer compliance frameworks with the UK Gambling Commission’s licensing requirements.

Regulatory Context and Responsible Gambling Obligations

The relationship between banking infrastructure and gambling regulation in the UK has grown considerably more complex since the Gambling Act 2005 was enacted. That legislation, designed for a pre-smartphone era, is currently undergoing its most significant review in two decades, with the Gambling Act Review white paper published in April 2023 introducing proposals around affordability checks, stake limits for online slots, and enhanced requirements for operators to share data with a statutory levy-funded research and treatment body.

Within this regulatory environment, the role of banks in supporting responsible gambling has attracted specific attention. The Gambling Commission has encouraged financial institutions to develop and promote gambling transaction controls, and Starling’s Gambling Block is frequently cited as an example of what proactive implementation looks like in practice. The Financial Conduct Authority, which regulates Starling as an authorised deposit-taking institution, has separately explored how open banking data might be used to identify customers at risk of financial harm — a category that overlaps meaningfully with problem gambling.

Starling has also been transparent about its approach to business banking for gambling operators themselves. The bank does not provide business accounts to gambling companies, a policy decision that reflects both risk appetite and reputational considerations, though it does not affect individual customers who use personal accounts to fund their betting activity at operators licensed by the Gambling Commission. This distinction is worth understanding clearly: Starling’s restrictions on the operator side do not translate into any restriction on individual customers making deposits at licensed sites using their personal Starling debit cards.

Practical Considerations for Bettors Using Starling

From a day-to-day operational perspective, bettors using Starling accounts encounter a relatively consistent experience across licensed UK operators. Deposits are generally processed instantly, as is standard for debit card transactions on Mastercard’s network. The minimum and maximum deposit limits are determined by the operator rather than the bank, though Starling does apply its own transaction monitoring processes as part of its anti-money laundering obligations under the Money Laundering, Terrorist Financing and Transfer of Funds Regulations 2017.

One area where bettors sometimes encounter friction is with operators that use third-party payment processors whose systems may not correctly identify Starling’s BIN (Bank Identification Number) ranges, occasionally causing transactions to be declined at the processor level rather than the bank level. This has become less frequent as Starling’s card base has expanded — the bank reported over three million personal current account customers by 2023 — but it remains a possibility worth being aware of. In such cases, contacting the operator’s customer support to confirm compatibility is typically the most efficient resolution path.

Withdrawals from betting accounts to Starling benefit from the bank’s real-time payment processing, meaning funds arriving via Faster Payments are credited immediately and visible in the app with a corresponding notification. This contrasts with some traditional bank accounts where incoming transfers may take several hours to appear despite the underlying payment having been received. For bettors who manage their bankroll actively or who want immediate visibility of returned funds, this responsiveness is a practical advantage rather than a marketing claim — it reflects the technical architecture of how Starling processes incoming payments at its core banking layer. Betzella has documented this operational pattern across multiple operator and payment method combinations, noting that Starling’s real-time credit behaviour is among the more consistent in the digital banking category.

Starling Bank’s emergence as a meaningful option for UK bettors reflects a broader convergence between financial technology and the gambling sector’s evolving payment infrastructure. The bank did not design its features specifically for bettors, but the combination of real-time notifications, transparent spending categorisation, and a user-controlled gambling block has made it a functionally well-suited option for those who want greater oversight of their betting expenditure. As the regulatory environment continues to develop under the Gambling Act Review, the intersection of banking controls and gambling behaviour is likely to attract further attention from both the Gambling Commission and the FCA — and the infrastructure that challenger banks like Starling have built may increasingly inform what regulators consider standard practice for financial institutions serving customers who bet. Betzella’s analysis of this space suggests that understanding the banking layer of gambling transactions is becoming as important as understanding the operators themselves.

For organisations interested in sponsoring the Social Impact Award, please contact Sam Cannon at [email protected] for more information.

The Medical Cannabis Clinicians Society (MCCS) is excited to support an essential event in the world of medical cannabis – the International Conference on the Science & Practice of Medical Cannabis (CT-Cann2024).

This prestigious conference is set to take place in London on the 29th and 30th of May, 2024, at the Hilton London Canary Wharf. Our endorsement of CT-Cann2024 highlights our commitment to advancing research and clinical practice in medical cannabis.

A landmark cannabis event

Last year’s conference was a landmark event, bringing together clinicians and experts for a rich dialogue on the latest developments in the field.

The Society is proud to have supported this vibrant forum, which made significant strides in medical cannabis discussions.

This year, the event has been renamed to International Conference on the Science & Practice of Medical Cannabis (CT-Cann2024) to reflect the growing scope of discussions around cannabis research and its practical applications in healthcare.

What’s in Store at CT-Cann2024

CT-Cann2024 is a forward-thinking platform for cannabinoid therapy advances. Led by co-chairs Prof. Dedi Meiri and Dr. Haggai Sharon, the event is set to showcase the most recent evidence and ideas in cannabinoid therapy.

The conference will bridge the latest scientific discoveries with clinical practices, providing insights into the effective use of cannabinoid-based treatments. It offers a unique chance for attendees to meet leading researchers, clinicians, and industry professionals from around the world, creating a space for the exchange of innovative ideas and practices.

Special Offer for MCCS Members

To show our appreciation for our members’ dedication to the field of medical cannabis, the MCCS is pleased to offer a special 15% discount on registration rates for CT-Cann2024.

This exclusive discount is our way of saying thank you to our members for their ongoing support and commitment.

Members who wish to take advantage of this offer should contact Rachel at [email protected] for more details and the discount code.

Join Us in London

As CT-Cann2024 draws near, we warmly invite our members and the broader community to join this significant event. Whether you’re a seasoned clinician, a researcher at the cutting edge of cannabis science, or an industry professional interested in the latest trends and applications, CT-Cann2024 promises to be an enlightening experience.

Let’s come together in London for CT-Cann2024, to be at the forefront of shaping the future of medical cannabis.

On 2 November 2023, as part of Medical Cannabis Awareness Week, the Cannabis Industry Council and the Medical Cannabis Clinicians Society is hosting an exclusive networking event in London.

Hosted at Gowling WLG, attendees will have the opportunity to meet and interact with a diverse, influential audience.

About the Event

Speakers

Dr. Dedi Meiri directs the Laboratory of Cancer Biology
and Cannabinoid Research, investigating cannabinoids’ therapeutic potential on diseases like cancer and epilepsy and spearheads the Database Project, profiling diverse cannabis strains and their medical relevance.

We are currently in the process of confirming a panel of speakers, with a keen emphasis on creating dynamic and thought-provoking conversations for our guests.

Over the next few weeks, we will continue our efforts in securing a range of additional high-profile speakers, offering a broad spectrum of expertise and viewpoints. The event will be a unique opportunity, open exclusively to leading stakeholders, including business leaders, MPs, policymakers and investors.

Sponsorship opportunities

As a sponsor, you will enjoy unparalleled exposure to an audience of industry professionals, clinicians, and influential stakeholders in the cannabis sector.

Support as a sole sponsor with a 15 minute speaking slot plus a range of other benefits.

To learn more and request the sponsorship packages in detail, please contact Hannah Deacon at [email protected].

 

The Medical Cannabis Clinicians Society is proud to officially endorse the 2nd International Congress on Clinical Trials on Cannabis, taking place on 15 & 16 February 2023 in London.

This unique conference – the only one of its kind in the UK – will inform participants of the latest evidence and concepts regarding cannabinoid therapy. It will aid prescribers to practically implement best practices based on the clinical implications of current research and expert opinions and serve as a platform for an exchange of ideas and practices in cannabinoid medicine.

Agenda and speakers

CT-Cann2023 will bring together global experts to discuss ways of improving current research strategies, new discoveries, practical dilemmas and future avenues in this rapidly evolving field. Ideal for MCCS members and those wishing to learn more about this treatment, the congress will include basic and clinical methodologies, new findings, regulatory and legal issues, pharmacological considerations, and technological advancements, emphasising practical implications for patients, researchers, prescribing clinicians and industry leaders.

The agenda is currently being confirmed with new speakers being added. The Preliminary speakers include:

The MCCS has secured a 15% discount for its members when you register before 21 December 2022. To become a member of the Society, join online today. 
Book Your Place

If you are a member and have not yet received the discount code, please contact us.

Call for Abstracts

The Congress Chairs invite the submission of original abstracts for Oral and/or Poster presentation – deadline 9 January 2023. Topics can include:

Just two and half years after launch, the Medical Cannabis Clinicians Society today reports over 300 members as it prepares to launch a series of in-person events for 2022.

Over 300 clinicians, including specialist consultants in a wide range of specialisms, GPs, nurses and allied health professionals, are now active members of the Society, sharing best practice, learning from each other, and accessing regular expert support.

In 2022, the Executive Committee is holding five in-person events – in Manchester on Thursday 12th May, in Belfast on 1st June, and in Edinburgh, Cardiff and London before the end of the year.

Medical Cannabis: Everything You Need to Know is described as a practical introduction to medical cannabis and CBD.

Open to clinicians, medical students, scientists, researchers, professionals and patients curious about medical cannabis and the current state of prescribing, evidence and availability in the UK, the evening events take place from 6:30pm for two hours, with networking and a panel Q&A for attendees following the speakers.

Prescribing doctors from the Society’s Executive Committee will be joined at each event by Chair, Professor Mike Barnes, by medical cannabis patients and by Sativa Learning’s Ryan McCreanor and Volteface’s Katya Kowalski who will present education opportunities and research insights.

The first event takes place at The Midland Hotel in Manchester at 6:30pm on Thursday 12 May.

Dr Niraj Singh, Consultant Psychiatrist from The Medical Cannabis Clinics and Executive Committee member of The Medical Cannabis Clinicians Society will share his experience of becoming a medical cannabis prescriber. Prof. Mike Barnes will explore the history and evidence for medical cannabis. Medical cannabis patient Emdad Khan will also join the event. 

 

Professor Mike Barnes, Chair of the Medical Cannabis Clinicians Society said:

“The growth we have seen in our membership over the last 2.5 years demonstrates the appetite the UK’s clinicians have to learn about this life-changing medication.

With significant restrictions meaning that only Specialist Consultants can prescribe, little to no cannabis education for medical students, and the fact that medical cannabis is only available via privately prescribing doctors, the number of clinicians choosing to educate themselves and access support via the Society should be noted by leaders in the health service and in Government.

Our programme of events, which will see us visit Manchester, Edinburgh, Belfast, Cardiff and London this year, and Liverpool, Newcastle, Bristol, Birmingham and Dublin in 2023, are a fantastic opportunity for clinicians and medical students particularly to learn the facts about this treatment and practical steps to prescribing.”

Hannah Deacon, Executive Director of the Medical Cannabis Clinicians Society, said:

“The Medical Cannabis Clinicians Society believes that everyone who could benefit from medical cannabis should have access to it. Our mission is to give clinicians access to evidence, training, expert guidance, peer support and licensed product information so they can prescribe life-changing medical cannabis treatments to all patients in the UK, on the NHS.

The Society is an expert-led, independent, not-for-profit community, dedicated to bringing this safe, legal and effective medicine to people living with chronic conditions.”

 

Medical cannabis training for UK doctorsExclusively for members of The Medical Cannabis Clinicians Society, every two months doctors and medical students have the opportunity to attend a half-day, live and interactive Zoom training session with Professor Mike Barnes.

Medical Cannabis Explained: everything you need to know to become a confident prescriber

The three-hour interactive medical cannabis training session for UK doctors covers:

Through the Society, members can already access training programmes which can be completed at your own pace, as well as a range of resources which cover the process of becoming a prescriber, products and frequently asked questions. With the launch of live training sessions in 2021, for the first time, members can book a live training session, sharing questions in advance.

To book your place, please visit Eventbrite and select your chosen date. Please add your full name and email address.

If you are not a member of the Society but wish to access the training, you can join the Society here. When your membership is confirmed, you will be able to book your place. Your booking will be cancelled and refunded if you are not a Society member.

The first MCCS and Drug Science roadshow took place in Birmingham on 27 February 2020.

Dr Leon Barron, Dr Elie Okirie, David Badcock (Drug Science) Hannah Deacon hosted the event which was attended by clinicians, medical students and those on placements, professionals from the pharmaceutical industry and other sector organisations. Over 50 attendees joined us at the event, which took place at The Medical School at The University of Birmingham. 

Dr Leon Barron presented an overview of medical cannabis – its history and evidence, as well as the role of the GP. Dr Elie Okirie talked about his route to becoming a prescriber, and presented a case study of a patient receiving medical cannabis treatment in the Midlands. Hannah Deacon talked about her experience as a patient advocate and her journey to change the law for her son, Alfie, and David Badcock introduced Project Twenty21.

Over the coming weeks we’ll be sharing further dates for Leeds, Brighton, Liverpool, Newcastle and Bristol. Attendance at our roadshow events is just £10, and it’s free for Society and Drug Science members.

Thanks to the GP Society at The University of Birmingham for hosting us.

The Medical Cannabis Clinicians Society and Drug Science are on tour from February 2020, bringing medical cannabis education and practical guidance to audiences across the UK.

Clinicians, medical students, scientists, researchers, professionals and patients curious about medical cannabis and the current state of prescribing, evidence and availability in the UK are welcome to join us at this practical introduction to medical cannabis and CBD.

As well as gaining an overview of the history and evidence of medical cannabis and CBD, you’ll hear from doctors currently prescribing this treatment, from scientists and researchers dedicated to creating the largest body of evidence for the effectiveness of medical cannabis in Europe and from medical cannabis patients currently being prescribed the treatment.

Book your tickets

With our first event taking place in Birmingham on 27 February, we’ll also be visiting Liverpool in March with dates still to confirm in Bristol, Cardiff, Edinburgh, Glasgow, Leeds, Manchester, Newcastle, Northampton and Sheffield.

Speakers include:

Society Executive Committee members:

Drug Science

Medical Cannabis Clinicians Society and Drug Science Community Members attend for free

Clinicians who sign up to become members of The Medical Cannabis Clinicians Society at the event will receive £10 off the usual £90 per year membership fee – making attendance at this event free of charge.

All Drug Science Community Members are invited free of charge. Our Community are our regular donors who commit £10 or more a month, and who play a critical role in helping us achieve our mission. To join, community, please see further details here. Once you become a member, you will be emailed your personal access code to attend this event.

If you are a member of either group, please contact us for your free access code.

Join the Medical Cannabis Clinicians Society at this exciting conference for clinicians interested in becoming prescribers and for sector professionals and others interested in the growth of access and the reality of medical cannabis in the UK today.

At Medical Cannabis in Practice: Prescribing, practicalities and the patient experience, you’ll learn from those at the heart of this new industry – from licensed producers working to grow and develop treatments, those working to import and ensure access through our pharmacies, and from doctors prescribing life-changing treatments.

Click to buy tickets now

Speakers will include Tonia Antoniazzi MP, Prof. Roger G Pertwee, Chair, Prof. Mike Barnes, Vice-Chair, Dr Dani Gordon and MCCS Committee Members Dr Leon Barron, GP, Dr Liz Iveson, Consultant Complex Care Physician, Dr Rebbeca Moore, Psychiatrist and Hannah Deacon, Executive Director and Patient Advocate.

With further speakers from across the medical cannabis sector soon to be announced, buy your tickets today and secure your place at this not-to-be missed event.

Interested in joining The Medical Cannabis Clinicians Society?

Membership is open to clinicians, nurses and other healthcare professionals interested in medical cannabis treatments. With peer support, training, evidence and exclusive discounts to events and conferences, find out more and join today by emailing [email protected].

You can also sign up during the event.

Chair Prof Mike Barnes, Vice-Chair, Dr Dani Gordon & Committee Member, GP Dr Leon Barron join Dr Christian Jessen & Dr Callie Seaman on The Medical Panel this weekend.

On Saturday 14 September from 12:45pm, the panel will take to the Business Pro Stage to explore medical cannabis in the UK today.

Find out more and book your place here: www.hempandcbdexpo.co.uk/buy-tickets 

Interested in joining The Medical Cannabis Clinicians Society?

Membership is open to clinicians, nurses and other healthcare professionals interested in medical cannabis treatments. With peer support, training, evidence and exclusive discounts to events and conferences, find out more and join today by emailing [email protected].